Strides Pharma Science

Strides Pharma jumps 12% on healthy Q3 operational performance

The management said Strides continues to deliver a strong performance in Q3FY26 with growth primarily driven by the Other Regulated Markets and Growth Markets.

Strides Pharma Q3FY26 results: Net profit doubles to ₹208.12 cr

Strides Pharma Science Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 208.12 crore in the third quarter ended December 31, 2025 on the back of robust sales growth and one time income on sale of property. The company had posted a consolidated net profit of Rs 90.04 crore in the corresponding quarter last fiscal, Strides Pharma Science Ltd said in a regulatory filing. Consolidated revenue from operations in the third quarter stood at Rs 1,194.65 crore as against Rs 1,153.67 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 1,052.7 crore as compared to Rs 1,043.96 crore in the same period a year ago, the company said. The company said during the third quarter it sold its investment property consisting of land and building for a consideration of Rs 112.87 crore and recorded a profit of Rs 102.14 crore as other income. Commenting on the performance, Strides Pharma Science MD & Group CEO, Badree Komandur, ...

Strides Pharma spurts 15%, hits all-time high on strong Q2 performance

Strides Pharma business outlook, in Q2 earnings update the company said the expansion of product portfolio and new customer acquisitions to drive growth.

Strides Pharma Q2FY26 results: Net profit jumps 82% to ₹131.5 crore

Strides Pharma Science Ltd on Friday reported an 82 per cent jump in consolidated net profit at Rs 131.52 crore in the second quarter ended September 30, 2025 on the back of strong revenue growth in 'other regulated markets' and lower expenses. The company had posted a consolidated net profit of Rs 72.3 crore in the corresponding period last fiscal, Strides Pharma Science said in a regulatory filing. Consolidated revenue from operations in the second quarter stood at Rs 1,220.83 crore as compared to Rs 1,166.93 crore in the year-ago period, it added. Total expenses in the quarter under review stood at Rs 1,085.03 crore as compared to Rs 1,104.61 crore in the same period last fiscal, the company said. Commenting on the performance, Strides Pharma Science MD & Group CEO, Badree Komandur said, "Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the 'other regulated markets'." In an investor presentation, the company said in Q2 FY26 'other ...

Dividend stocks: These 8 stocks to go ex-date on July 22; do you own any?

Here is the complete list of stocks that will trade ex-date tomorrow, July 22, along with their key announcement details

Strides Pharma initiates Class-II recall of Testosterone Gel in US

The recall was voluntarily initiated by Strides Pharma on March 5, 2025, and remains ongoing. Consignees have been informed about this recall formerly, although public press release has not been issue

Strides Pharma Science share price gains 3% on demerger news; details here

The proposed structure, the company said, envisages the NewCo to be a WOS of Strides and there will not be any impact on Strides, financially or otherwise, arising out of the proposed restructuring

This Mukul Agrawal portfolio pharma stock surged 12% in subdued market

Shares of Strides Pharma Science surged 12 per cent to Rs 736.05 on the BSE in Wednesday's intra-day trade in an otherwise subdued market

Strides Pharma Q2 results: Net profit at Rs 93.7 cr, revenue up 20%

US revenue hitting quarterly high, sustained growth across markets among reasons

Strides Pharma CDMO arm gets Rs 801 cr from investors in pre-listing round

Strides Pharma Science on Wednesday said its associate firm has received equity commitment of Rs 801 crore from domestic and foreign institutional investors in the pre-listing round. OneSource Specialty Pharma, the contract development and manufacturing organisation (CDMO) arm of the company, has received confirmed capital infusion commitments from investors, Strides Pharma Science said in a statement. The share subscription agreements are being executed at a pre-money equity value of USD 1.65 billion, it added. The fundraise is in line with the scheme of arrangement announced in September 2023 and the investment is subject to customary closing conditions, including receipt of necessary regulatory approvals, the company said. "This fundraise will enable us to accelerate our growth plans, right-size our debt book, and commit significant new capex for a strong order book across our three platforms," Strides Group Founder Arun Kumar said. In September last year, Strides announced t

Strides Pharma gets shareholders' nod to set up speciality pharma CDMO

Strides Pharma Science on Wednesday said it has received approval from shareholders and secured creditors for creation of OneSource -- a specialty pharma CDMO (contract development and manufacturing organization). The company has secured the approval of its shareholders and secured creditors with overwhelming majority, along with those of OneSource Specialty Pharma and SteriScience Specialties, in meetings convened under the guidance of the National Company Law Tribunal, it said in a regulatory filing. All the secured creditors who voted on the scheme for the three companies in their respective meetings were in favour of the scheme, it added. "We believe OneSource will unlock considerable value for Strides' stakeholders upon its listing. We remain committed to delivering on this promise and express our gratitude to our shareholders and creditors for their continued trust and support," Strides Pharma Science Executive Chairperson Arun Kumar said. In September 2023, Strides announced

Strides Pharma falls over 4% after USFDA gives VAI tag to Chennai facility

Strides Alathur facility caters to the US and Other Regulated Markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets

Vinay Rajani of HDFC Securities suggests buying these stocks on July 24

From the low, Nifty recovered 470 points towards 24544 and ended the session at 24479.

Strides Pharma rises 3% after US FDA approves Hypocalcemia drug

The rise came after the company announced that the United States Food and Drug Administration (US FDA) has approved its Sevelamer carbonate tablets 800 mg

Strides Pharma gets USFDA approval for Levetiracetam Oral Solution

The Levetiracetam Oral Solution has a market size of around $55 million, according to data reported by IQVIA

Strides Pharma arm obtains USFDA nod for Levetiracetam oral solution

According to market research firm IQVIA, the Levetiracetam oral solution has a market size of $55 million

Strides Pharma Q2 net loss at Rs 149 cr, revenue crosses Rs 1,000 cr

Total income, however, rose to Rs 1,035 crore in the second quarter as compared to Rs 920 crore in the year-ago period, Strides Pharma said in a regulatory filing

Strides Pharma to spin off CDMO, gelatin business into separate entity

OneSource is created by merging Strides' soft-gel business and SteriScience CDMO injectables business into current Stelis

Strides Pharma to spin off CDMO, soft gelatin biz into a new entity

The company's board has approved a scheme of arrangement amongst Strides Pharma Science, Steriscience Specialties and Stelis Biopharma, the drug firm said in a regulatory filing

Strides Pharma soars 8% on USFDA nod for drug to treat heart diseases

Meanwhile, Strides said the board is scheduled to meet on September 25, to consider the combine CDMO interests of the group to become one of India's top specialty pharmaceuticals CDMOs